What is the appropriate apixaban (Eliquis) dose for a patient with an estimated glomerular filtration rate (eGFR) less than 15 mL/min?

Apixaban Dosing in eGFR <15 mL/min

For patients with atrial fibrillation and eGFR <15 mL/min (including those on dialysis), apixaban can be used at either 5 mg or 2.5 mg twice daily, with the dose determined by the two-of-three dose-reduction criteria (age ≥80 years, weight ≤60 kg, serum creatinine ≥1.5 mg/dL)—not by renal function alone. 1

FDA-Approved Dosing Framework

The FDA label explicitly permits apixaban use across the entire spectrum of renal function, including end-stage renal disease (ESRD) on dialysis, with dosing based solely on clinical characteristics rather than kidney function 1:

• Standard dose (5 mg twice daily) is appropriate unless the patient meets at least two of the following three criteria 1:

  • Age ≥80 years
  • Body weight ≤60 kg
  • Serum creatinine ≥1.5 mg/dL

• Reduced dose (2.5 mg twice daily) is indicated only when two or more of these criteria are present 1

• Meeting only one criterion does not warrant dose reduction 2

Guideline Consensus for Severe CKD/ESRD

Multiple major guidelines support apixaban use in patients with eGFR <15 mL/min, though with varying levels of certainty 3:

• 2019 AHA/ACC/HRS guidelines recommend apixaban 5 mg or 2.5 mg twice daily (based on the two-of-three criteria) for patients with CrCl <15 mL/min or on dialysis 3

• 2018 CHEST guidelines (U.S. only) recommend 5 mg twice daily for dialysis patients, applying the standard dose-reduction criteria 3

• 2018 KDIGO suggests considering 2.5 mg twice daily in this population, acknowledging equipoise regarding warfarin versus apixaban 3

• European guidelines (ESC 2016, EHRA 2018) generally do not recommend apixaban in this population, reflecting regional regulatory differences 3

Pharmacokinetic Considerations

The rationale for permitting apixaban in severe renal impairment stems from its favorable pharmacokinetic profile 1:

• Only 27% renal clearance, with the majority eliminated hepatically and via direct intestinal excretion 1

• In ESRD patients on hemodialysis, apixaban exposure is only 36% higher compared to those with normal renal function when dosed post-dialysis 1

• Dialysis clearance of apixaban is minimal (approximately 18 mL/min), and systemic exposure is actually 14% lower during dialysis versus off-dialysis 1

• The modest increase in exposure (44% in severe impairment with CrCl 15 mL/min) does not necessitate dose adjustment based on renal function alone 4

Evidence on Safety and Efficacy

Recent observational data suggest the 2.5 mg dose may be safer in severe CKD:

• A 2023 study of 4,313 patients with CKD stage 4/5 found that 5 mg twice daily was associated with 63% higher bleeding risk compared to 2.5 mg twice daily (subdistribution HR 1.63,95% CI 1.04-2.54), with no difference in stroke/systemic embolism or mortality 5

• This supports a more conservative approach, favoring the 2.5 mg dose in patients with eGFR <30 mL/min when clinically appropriate 5

• Multiple real-world studies demonstrate that apixaban (particularly at reduced doses) is associated with lower bleeding risk than warfarin in patients with severe CKD, including those with eGFR <30 mL/min 6, 7

Practical Dosing Algorithm

For patients with atrial fibrillation and eGFR <15 mL/min:

1. Count the number of dose-reduction criteria present (age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL) 1

2. If ≥2 criteria are met: Use 2.5 mg twice daily 1

3. If 0-1 criteria are met: The FDA permits 5 mg twice daily, but given the 2023 bleeding data, strongly consider 2.5 mg twice daily in all patients with eGFR <15 mL/min regardless of other criteria 5

4. For dialysis patients: Either dose is permissible; timing relative to dialysis is not critical given minimal dialysis clearance 1

Critical Caveats and Monitoring

• Underdosing is the most common apixaban prescribing error (occurring in 9.4-40.4% of prescriptions), often from inappropriately applying the 2.5 mg dose when only one criterion is met 2

• However, in severe CKD/ESRD, the greater concern is bleeding risk from overdosing, making the 2.5 mg dose more defensible even with fewer than two criteria 5, 8

• Rare but catastrophic bleeding (pleural, pericardial, intracranial) has been reported in ESRD patients on apixaban, even with guideline-based dosing 8

• Concomitant antiplatelet therapy dramatically increases bleeding risk and should be avoided when possible 9

• Drug level monitoring may be considered in high-risk patients, though target ranges are not established; levels consistently >100 ng/mL or below detection may warrant dose adjustment 9

• Warfarin remains an alternative, though it carries risks of vascular calcification in CKD and requires more intensive monitoring 3